Novo Nordisk (NVO) announced Thursday it will start a late-stage clinical program next year to evaluate its new obesity therapy amycretin in subcutaneous and oral formulations. Amycretin, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results